Trial · NCT07886385
Differential Absorption Kinetics of Grape Seed Extract Polyphenols
NCT07886385, Not applicable, Not yet recruiting, Clinical Nutrition Research Center, Illinois Institute of Technology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Differential Absorption Kinetics of Grape Seed Extract Polyphenols. Trials, record NCT07886385. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886385
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Differential Absorption Kinetics of Grape Seed Extract Polyphenols
- NCT number
- NCT07886385
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
- Conditions
- Healthy Adults
- Interventions
- MN-BP Grape Seed Extract, Commercially Available Grape Seed Extract, Gen 2 GSE - Monomer-Enriched, Gen 2 GSE - Oligomer-Enriched, Gen 2 GSE - Polymer-Enriched, Gen 2 GSE - Mixture
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma concentrations of GSE-derived (poly)phenols and their metabolites | Baseline through 24 hours after GSE consumption | Plasma concentrations of parent GSE-derived (poly)phenolic compounds and their metabolites will be measured using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) at different time points following each GSE intervention. |
| Primary | Urinary concentrations of GSE-derived (poly)phenols and their metabolites | Baseline through 24 hours after GSE consumption | Urine samples will be analyzed using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) to quantify GSE-derived (poly)phenolic compounds and their metabolites following each GSE intervention |
| Secondary | Bioavailability of GSE-derived (poly)phenols and their metabolites | Baseline through 24 hours after GSE consumption | GSE-derived (poly)phenolic compounds and their metabolites will be identified and quantified in plasma and urine using ultra-high-performance liquid chromatography and mass spectrometry (UHPLC-MS). |
| Secondary | Plasma metabolite profiles following GSE consumption | Baseline through 24 hours after each GSE intervention | GSE-derived metabolites will be identified in plasma using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) to characterize the metabolite profiles associated with the different GSE preparations. |
| Secondary | Urinary metabolite profiles following GSE consumption | Baseline through 24 hours after each GSE intervention | GSE-derived metabolites will be identified in urine using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) to characterize the urinary metabolite profiles associated with the different GSE preparations |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886385
GET https://conductscience.org/api/trials/v1/NCT07886385/registered